No single blood test can confirm Hodgkin’s lymphoma on its own. Diagnosis ultimately requires a tissue biopsy showing the characteristic Reed-Sternberg cells. But blood work plays a surprisingly large role in raising suspicion, gauging severity, guiding treatment decisions, and tracking whether the disease is responding to therapy. The tests that matter range from a routine complete blood count to specialized biomarkers that most people have never heard of, and understanding which results doctors are watching for can make the diagnostic process less opaque.
The Complete Blood Count
A complete blood count is usually the first blood test ordered when someone shows up with persistent swollen lymph nodes, unexplained fevers, drenching night sweats, or weight loss. In Hodgkin’s lymphoma, several CBC values tend to shift in recognizable ways, though none of them are unique to the disease. White blood cell counts may be elevated, sometimes markedly so. A white cell count above 15,000 per cubic millimeter is one of seven adverse prognostic factors identified in a landmark study that shaped how advanced Hodgkin’s disease is staged and treated today.1PubMed. A prognostic score for advanced Hodgkin’s disease At the same time, the lymphocyte count within that white cell total is often low. A lymphocyte count below 600 per cubic millimeter, or below 8 percent of the total white cells, is another one of those seven factors.
Hemoglobin frequently drops. Many patients present with anemia, and a hemoglobin level below 10.5 g per deciliter signals worse outcomes.1PubMed. A prognostic score for advanced Hodgkin’s disease The anemia can result from the disease itself suppressing normal blood-cell production in the bone marrow, from chronic inflammation, or in rare cases from the immune system attacking its own red blood cells. Platelet counts are also worth watching. Elevated platelets at diagnosis have been linked to worse progression-free survival in pediatric Hodgkin’s lymphoma, and elevated eosinophils (a particular type of white blood cell) showed independent prognostic value in the same population.2PubMed. The prognostic value of biological markers in paediatric Hodgkin lymphoma
Researchers have also begun calculating ratios from CBC numbers. The neutrophil-to-lymphocyte ratio, the platelet-to-lymphocyte ratio, and composite indices that combine several cell counts into a single inflammation score have all been studied as ways to estimate how aggressive the disease is at diagnosis.3Taylor & Francis Online / Biomarkers. Systemic inflammatory burden at diagnosis predicts survival in Hodgkin lymphoma: a comprehensive evaluation of the Complete Blood Count Score Model These ratios are still being validated, but they illustrate a broader point: sometimes the pattern of changes across a standard blood panel tells you more than any single number.
Erythrocyte Sedimentation Rate and C-Reactive Protein
Two of the oldest and simplest lab tests remain remarkably useful in Hodgkin’s lymphoma. The erythrocyte sedimentation rate, or ESR, measures how quickly red blood cells settle to the bottom of a test tube over one hour. It rises with inflammation of almost any kind, but in Hodgkin’s disease the elevation can be dramatic, and the pattern of that elevation carries real clinical weight. A study of early-stage patients found that ESR patterns were the single best predictor of early relapse and survival, outperforming even the type of initial chemotherapy given. Patients with the most unfavorable ESR patterns had a roughly seven-fold higher risk of death compared to those with favorable patterns, and when early relapse was layered on top of an unfavorable ESR, the risk of death climbed to about fifteen times higher.4PubMed. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease An ESR above 40 mm per hour also appeared as a significant prognostic variable in analyses of more advanced disease.5British Journal of Cancer. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease
C-reactive protein, or CRP, is another general marker of inflammation and serves a complementary role. Elevated CRP at baseline in Hodgkin’s lymphoma patients has been associated with a greater likelihood of “B symptoms” (the constellation of fevers, night sweats, and weight loss that signals more active disease) and of advanced-stage disease at diagnosis.6Hematology, Transfusion and Cell Therapy. Evaluation of C-reactive protein and its prognostic relationship in patients with Hodgkin’s Lymphoma Neither ESR nor CRP can diagnose Hodgkin’s on its own, but when these markers are sharply elevated in someone with unexplained lymph node enlargement, they push the clinical suspicion much higher.
Lactate Dehydrogenase
Lactate dehydrogenase, commonly written as LDH, is an enzyme found in most cells. When cells are damaged or turning over rapidly, LDH spills into the bloodstream. In Hodgkin’s lymphoma, an LDH above the normal range has emerged as one of the most powerful standalone prognostic markers. A study of Hodgkin’s disease patients found that an LDH above 320 U/mL was an independent predictor of three distinct outcomes: the probability of achieving complete remission, the probability of relapse, and overall survival. In both single-factor and multi-factor statistical models, LDH retained its prognostic significance, making it one of the most broadly informative individual lab values in the disease.5British Journal of Cancer. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease
LDH is routinely measured in any lymphoma workup, and it is helpful precisely because it is nonspecific. An elevated value does not point to Hodgkin’s lymphoma specifically, but in a patient already suspected of having it, a high LDH signals a heavier disease burden and a more urgent need for aggressive treatment.
The International Prognostic Score
Several of the blood values described above were pulled together into a single scoring system in the late 1990s, and that system still shapes how oncologists talk to patients about their outlook. Known as the International Prognostic Score, or IPS, it identified seven factors with roughly equal independent weight in predicting outcomes for advanced Hodgkin’s disease. Four of the seven come directly from blood tests: a serum albumin level below 4 g per deciliter, a hemoglobin below 10.5 g per deciliter, a white cell count of 15,000 or more per cubic millimeter, and a lymphocyte count below 600 per cubic millimeter (or below 8 percent of the total white cells).1PubMed. A prognostic score for advanced Hodgkin’s disease The remaining three factors are age (45 or older), male sex, and stage IV disease.
Each factor a patient has counts as one point, with more points predicting worse freedom from progression. The score was originally developed for patients receiving frontline chemotherapy, but subsequent work showed it also predicts outcomes for patients who need more intensive treatment, such as stem cell transplant. In that setting, low albumin, anemia, older age, and lymphocytopenia were independently associated with shorter event-free survival.7Annals of Oncology. The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation Low albumin in particular is an underappreciated red flag. It reflects systemic inflammation and poor nutritional status, and its prognostic weight holds up across different treatment scenarios.
Beta-2 Microglobulin
Beta-2 microglobulin is a small protein shed from the surface of nearly all cells in the body, but lymphoid tissue produces it in especially large quantities. In blood cancers, elevated beta-2 microglobulin generally correlates with heavier tumor burden, and that relationship holds in Hodgkin’s lymphoma. A comprehensive analysis of over 900 Hodgkin’s patients treated with standard chemotherapy found that beta-2 microglobulin had prognostic significance, though the underlying reasons remain somewhat murky. Some researchers believe it reflects tumor burden directly, while others suspect it captures something about the biology of the lymphoma that goes beyond simple disease volume.8PubMed Central. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients It is not part of the standard IPS, but many centers measure it as an additional data point, especially when the clinical picture is borderline.
Newer Biomarkers on the Horizon
Beyond the traditional blood panel, several emerging biomarkers are changing how researchers think about Hodgkin’s lymphoma detection and monitoring.
TARC (Thymus and Activation-Regulated Chemokine)
The Reed-Sternberg cells that define classic Hodgkin’s lymphoma produce large amounts of a signaling molecule called TARC, also known as CCL17. Because this protein floods into the bloodstream, serum TARC levels tend to be strikingly elevated in Hodgkin’s patients. What makes TARC especially interesting is the timeline: one study measuring levels in blood samples collected before patients were ever diagnosed found elevated TARC as early as six years before the clinical diagnosis. At the time of diagnosis itself, patients had an estimated 18.6-fold higher TARC level compared with matched controls.9PubMed Central. Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years TARC is increasingly used during treatment to monitor response, since levels drop sharply when therapy is working and can rebound before imaging detects a relapse.
Cytokines and Soluble Receptors
Hodgkin’s lymphoma is unusual among cancers in that the actual tumor cells make up only a tiny fraction of the tumor mass. The rest is an elaborate immune microenvironment of bystander cells that the Reed-Sternberg cells recruit and manipulate. This biology means the disease throws off a distinctive cocktail of immune signaling molecules into the blood. Elevated serum levels of soluble CD30, interleukin-6 (IL-6), and detectable interleukin-10 have all been found in blood samples taken before diagnosis, suggesting they may reflect the early activity of nascent tumor cells or the immune system’s response to them.10PubMed Central. Elevated serum levels of sCD30 and IL-6 and detectable IL-10 precede classical Hodgkin lymphoma diagnosis Staining of diagnostic tissue has confirmed that IL-6 and soluble IL-2 receptor are produced by the Reed-Sternberg cells themselves, not just by surrounding immune cells.11Clinical Cancer Research. Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma These markers are still primarily research tools rather than routine clinical tests, but they highlight a future in which a blood draw may provide much more granular information about the tumor’s behavior.
Circulating Tumor DNA
Liquid biopsy, the detection of tumor DNA fragments circulating freely in the bloodstream, is one of the most exciting frontiers in lymphoma monitoring. In a prospective study of classical Hodgkin’s lymphoma, researchers tracked specific gene mutations in blood plasma alongside standard PET scans during treatment. In one telling case, circulating tumor DNA was detectable at diagnosis, disappeared after the first two cycles of chemotherapy (matching a clean interim PET scan), and then reappeared at the point of treatment failure, concordant with the imaging results.12Haematologica. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study The appeal is obvious: a blood test that can track residual disease or early relapse without radiation exposure. Circulating tumor DNA is not yet part of standard Hodgkin’s workups, but clinical trials are actively exploring when and how to use it.
Epstein-Barr Virus Testing
Epstein-Barr virus (EBV), the virus behind infectious mononucleosis, is found inside the tumor cells of a substantial proportion of Hodgkin’s lymphoma cases. Quantifying EBV DNA in the blood at diagnosis gives doctors another data point about prognosis. One prospective study measured whole-blood EBV DNA in newly diagnosed Hodgkin’s patients and found it to be a significant prognostic marker.13PubMed. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma EBV status also matters because EBV-positive and EBV-negative Hodgkin’s lymphomas are increasingly understood as biologically distinct diseases that may eventually be treated differently.
It is worth noting that EBV is extremely common in the general population, so a positive EBV antibody test alone is meaningless. The relevant test is a quantitative measurement of viral DNA in the blood, which reflects active viral replication or tumor-cell shedding rather than a past infection.
Organ Function Tests and Unusual Findings
Before starting chemotherapy, doctors order a battery of tests to assess how well the liver, kidneys, and other organs are functioning. These are not diagnostic for Hodgkin’s, but they shape treatment decisions. Liver involvement is uncommon at initial presentation, but when it does occur, it can severely impair liver function and limit which chemotherapy drugs are safe to use. Case reports describe patients whose liver enzymes were so elevated that standard first-line chemotherapy had to be delayed in favor of gentler drugs until function improved.14PubMed Central. A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD Alkaline phosphatase, one of the liver enzymes, also appeared as a prognostic factor in some analyses of Hodgkin’s disease outcomes.
Occasionally, blood tests reveal something truly unexpected. Hodgkin’s lymphoma can trigger autoimmune phenomena in which the body’s immune system attacks its own blood cells. Autoimmune hemolytic anemia, where red blood cells are destroyed by antibodies, has been reported at diagnosis, though it is rare. In a review of over 1,000 Hodgkin’s patients, autoimmune hemolytic anemia was identified at presentation in about 0.2 percent of cases, and autoimmune destruction of platelets in about 0.3 percent.15PubMed. Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma The mechanism is unclear but may involve antibodies produced by the tumor cells themselves or a broader immune dysregulation triggered by the disease.16PubMed Central. Autoimmune Hemolytic Anemia and Hodgkin’s Disease: An Unusual Pediatric Association If you develop unexplained anemia that does not respond to iron supplements, especially alongside swollen lymph nodes, this is a combination worth investigating further.
Blood Tests During Treatment
Once chemotherapy begins, the blood panel transforms from a diagnostic tool into a safety monitor. Most chemotherapy regimens used for Hodgkin’s lymphoma suppress the bone marrow, dropping white blood cell and platelet counts. Neutropenia, a drop in the type of white cells that fight bacterial infections, is one of the most common and dangerous side effects. Across cancer patients receiving chemotherapy, the frequency of neutropenia has been reported at roughly 22 to 28 percent before and after treatment cycles.17PubMed Central. Differences in the count of blood cell counts pre-and post-chemotherapy in patients with cancer: a retrospective study Doctors check blood counts before each cycle to ensure counts have recovered enough to safely proceed.
Beyond safety monitoring, some of the same markers used at diagnosis are tracked during treatment to assess response. ESR, LDH, and especially TARC are all expected to normalize as treatment works. A machine learning study in pediatric Hodgkin’s patients explored whether changes in affordable blood tests, including ferritin, LDH, ESR, albumin, white cell count, and absolute lymphocyte count after two cycles of chemotherapy, could predict interim PET scan results.18PubMed Central. Machine Learning to Predict Interim Response in Pediatric Classical Hodgkin Lymphoma Using Affordable Blood Tests The goal is compelling, particularly in settings where PET scanners are not readily available: using routine blood draws to estimate whether a patient is on track.
How Blood Tests in Children Differ
Hodgkin’s lymphoma in children and adolescents behaves similarly to the adult disease but comes with a few distinctive blood-test wrinkles. Eosinophils, a type of white blood cell associated with allergic reactions and parasitic infections, appear to have independent prognostic value in pediatric Hodgkin’s that gets less attention in adult staging. One study found that elevated eosinophils and elevated ferritin at diagnosis each predicted worse five-year progression-free survival in children, even after accounting for disease stage. Eosinophil counts maintained their predictive value independently of interim PET scan results, suggesting they capture something about the biology of pediatric Hodgkin’s that imaging alone misses.2PubMed. The prognostic value of biological markers in paediatric Hodgkin lymphoma Ferritin, an iron-storage protein that also rises with inflammation, is measured routinely in pediatric workups and serves double duty as both a marker of iron status and a gauge of inflammatory activity.
When Blood Work Points the Wrong Way
One of the trickiest aspects of interpreting blood tests for Hodgkin’s lymphoma is that many of the abnormalities overlap with far more common conditions. Infectious mononucleosis, caused by EBV, deserves special mention. Mono can cause dramatic lymph node swelling, sky-high inflammatory markers, abnormal liver enzymes, and atypical lymphocytes on the blood smear that look alarming under a microscope. In a study of mononucleosis cases mimicking lymphoma, nearly half had cells resembling Reed-Sternberg cells on biopsy, the very hallmark of Hodgkin’s.19PubMed Central. Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features This overlap means that a young person presenting with swollen neck nodes, elevated ESR, abnormal liver function, and positive EBV antibodies could have either condition, and the blood work alone cannot reliably tell them apart. A biopsy with proper immunostaining is the only way to definitively distinguish mono from Hodgkin’s.
Other infections, autoimmune diseases like lupus, and even other cancers can produce blood profiles that look strikingly similar to Hodgkin’s on paper. The practical takeaway is that blood tests narrow the field, quantify risk, and track progress, but they cannot replace a pathologist looking at tissue under a microscope. Anyone whose blood work raises concern should expect a biopsy as the definitive next step, not more blood draws.